Alios BioPharma, developer of anti-viral therapies, has tacked $8 million onto its first round of funding, bringing its total to $32 million. The new money came solely from SR One. Based in South San Francisco, the company plans to use the money to push its lead compound past phase-one trials.

Alios brought in the initial $24 million from Novartis Ventures, Novo AS and Roche Venture Fund.

Next Story: HP funds 60 researchers at 46 universities Previous Story: Analog is dead! Long live digital TV!

Print Email Twitter Facebook Google Buzz LinkedIn Digg StumbleUpon Reddit Delicious Google More&8230'

Companies: Alios BioPharma, Novartis Ventures, Novo A/S, Roche Venture Fund

Companies: Alios BioPharma, Novartis Ventures, Novo A/S, Roche Venture Fund

Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.

VentureBeat has new weekly email newsletters. Stay on top of the news, and don't miss a beat.